期刊文献+

68Ga标记药物研究进展 被引量:5

The Research Progress of 68Ga Generator and 68Ga Radiopharmaceuticals
下载PDF
导出
摘要 正电子发射型计算机断层显像(positron emission tomography,PET)是核医学领域重要的诊断及显像工具,在基础医学诊断、新药研发和疗效评价等各方面发挥越来越重要作用。18 F是PET显像最常用的核素,但18 F需要加速器生产。68 Ga为PET显像核素,可以从长寿命的68 Ge/68 Ga发生器装置获得,不必依赖加速器。随着配位化学的发展,各种双功能螯合剂用于68 Ga的标记,可将68 Ga与多种化学结构及生物分子连接并且可以药盒化68 Ga标记药物。本文主要介绍近期68 Ga标记放射性药物的研究进展。 Positron emission tomography(PET)is an important diagnosis and imaging tool for nuclear medicine,and playing an increasing part in fundamental medicine,new drug research and clinical effect assessment,etc.18 F is the most common radionuclide for PET imaging,which is produced in a cyclotron.68 Ga is a PET imaging radionuclide of increasing concern,and is gained from long-lived 68 Ge/68 Ga generator systems.The use of 68 Ga does not demandan on-site cyclotron,which provide a convenient method for researchers.With the development of coordination chemistry,a variety of bifunctional chelators have been developed for 68 Ga labeling,which allow the convenient coupling tomany chemical structures and biomolecules.Kit-formulated preparation is another advantage for 68 Ga radiopharmaceuticals.This review presents the developments of the 68 Ga-based radiopharmaceuticals.
作者 郭志德 张现忠 杜进 GUO Zhide;ZHANG Xianzhong;DU Jin(Department of Isotope,China Institute of Atomic Energy,Beijing 102413,China;Center for Molecular Imaging and Translational Medicine,School of Public Health,Xiamen University,Xiamen 361102,China;China Isotope&Radiation Corporation,Beijing 100045,China)
出处 《同位素》 CAS 2019年第5期360-374,I0004,共16页 Journal of Isotopes
基金 博士后创新人才支持计划(BX201700142) 中国博士后科学基金面上项目(2018M630732) 国家自然科学基金(81471707)
关键词 PET显像 68 Ga发生器 68 Ga标记药物 positron emission tomography 68 Ga generator 68 Ga radiopharmaceuticals
  • 相关文献

参考文献3

二级参考文献139

  • 1Kohler G;Milstein C.Continuous cultures of fused cells secreting antibody of predefined specificity,1975(256).
  • 2Modlin IM,Oberg K,Chung DC,Jensen RT,de Herder WW,Thakker RV,Caplin M,Delle Fave G,Kaltsas GA,Krenning EP,Moss SF,Nilsson O,Rindi G,Salazar R,Ruszniewski P,Sundin A.Gastroenteropancreatic neuroendocrine tumours. The Lancet Oncology . 2008
  • 3RT Jensen,JF Battey,ER Spindel,RV Benya.International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacology Reviews . 2008
  • 4Solcia,E,Kloppel,G,Sobin,LH. World Health Organization International histological classification of tumors. Histological typing of endocrine tumors . 2000
  • 5Mirco Bartolomei,Lisa Bodei,Concetta Cicco,Chiara Maria Grana,Marta Cremonesi,Edoardo Botteri,Silvia Melania Baio,Demetrio Aricò,Maddalena Sansovini,Giovanni Paganelli.Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma[J]. European Journal of Nuclear Medicine and Molecular Imaging . 2009 (9)
  • 6I. Buchmann,M. Henze,S. Engelbrecht,M. Eisenhut,A. Runz,M. Sch?fer,T. Schilling,S. Haufe,T. Herrmann,U. Haberkorn.Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours[J]. European Journal of Nuclear Medicine and Molecular Imaging . 2007 (10)
  • 7P. Antunes,M. Ginj,H. Zhang,B. Waser,R. P. Baum,J. C. Reubi,H. Maecke.Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?[J]. European Journal of Nuclear Medicine and Molecular Imaging . 2007 (7)
  • 8Wouter A. P. Breeman,Alfons M. Verbruggen.The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?[J]. European Journal of Nuclear Medicine and Molecular Imaging . 2007 (7)
  • 9Sophia Koukouraki,Ludwig G. Strauss,Vassilios Georgoulias,Michael Eisenhut,Uwe Haberkorn,Antonia Dimitrakopoulou-Strauss.Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy[J]. European Journal of Nuclear Medicine and Molecular Imaging . 2006 (10)
  • 10Damian Wild,J?rg S. Schmitt,Mihaela Ginj,Helmut R. M?cke,Bert F. Bernard,Eric Krenning,Marion Jong,Sandra Wenger,Jean-Claude Reubi.DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals[J]. European Journal of Nuclear Medicine and Molecular Imaging . 2003 (10)

共引文献19

同被引文献43

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部